The researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a “prodrug” — a medicine designed to release its payload in a particular area of the body and in no other areas. The Johns Hopkins-discovered prodrug, called DRP-104 (sirpiglenastat), is in early-stage clinical trials in people with advanced solid tumors. The newly published studies in mice show that the augmented drug preferentially eliminates cancer cells but does not harm healthy cells.
A report of their experiments is published in Science Advances.
“Our goal was to modify an old cancer drug that had shown robust efficacy but was too toxic, especially to the gut, to be developed clinically. To do this, we used a prodrug approach. What is unique about our approach is that we utilized a novel chemistry design to create a prodrug that was simultaneously bio-activated in cancer cells but bio-inactivated in healthy tissues such as the gut. This preferential targeting of the payload to cancer cells is now enabling this efficacious class of drugs to be reevaluated safely in people,” says the study author.
The newly modified prodrug takes advantage of a common property of cancer cells: a voracious appetite for an amino acid called glutamine, which is a critical building block for proteins, lipids and nucleotides, as well as for energy formation. Rapidly growing cancer cells use a tremendous amount of glutamine, a phenomenon called “glutamine addiction,” but other healthy cells with rapid turnover, like those lining the gut, also rely on glutamine.
A co-author says, “DRP-104 is a tumor-targeted prodrug of the glutamine mimic drug called DON (6-Diazo-5-Oxo-L-norleucine), which inhibits multiple glutamine-utilizing enzymes in cancer cells. Many early studies of DON showed it was robustly efficacious in people and mice, but its development was halted due to its toxicity to normal tissues, especially the gut.”
Development of this promising class of drugs did not resume until the team decided to make chemical modifications to DON.
"We added chemical groups, called promoieties, to DON that rendered it inactive in the body until it reached the tumor, where the promoieties were clipped off by enzymes that are abundant in the tumor but not in the gut,” says the author. “This specific prodrug design made DON targeted to its intended destination (tumor) and have less of an impact on healthy cells elsewhere.”
For the new study, researchers gave the original DON drug and the souped-up DRP-104 drug to mice implanted with tumors. In mice that received DRP-104, the researchers found 11 times more active drug in the tumor compared with the gastrointestinal tract (gut). Both drugs completely wiped out the tumor, but DON caused more gut toxicity in the mice than DRP-104.
https://www.science.org/doi/10.1126/sciadv.abq5925
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fdiscovery-of-drp-104-a&filter=22
Targeting cancer cells big appetite for glutamine with a 'prodrug'
- 700 views
- Added
Edited
Latest News
Propionic acid protects ner…
By newseditor
Posted 28 Jan
How cells prevent harmful e…
By newseditor
Posted 28 Jan
Structured cerebellar conne…
By newseditor
Posted 28 Jan
Origins of pleasurable touc…
By newseditor
Posted 25 Jan
Unknown way cells protect t…
By newseditor
Posted 25 Jan
Other Top Stories
Pro-metastatic extracellular vesicles from chemotherapy in breast c…
Read more
The body's largest cell receptor crystallized!
Read more
Two Ways Cancer Resists Treatment Are Actually Connected, with One…
Read more
Second visual system in mouse cerebral cortex
Read more
Where will the world's next Zika, West Nile or Dengue virus come from?
Read more
Protocols
Machine learning prediction…
By newseditor
Posted 09 Jan
Differentiating PC12 cells…
By newseditor
Posted 09 Jan
Ultrasensitive sensors reve…
By newseditor
Posted 05 Jan
In vitro-derived medium spi…
By newseditor
Posted 04 Jan
Molecular and spatial signa…
By newseditor
Posted 30 Dec
Publications
Brainstem networks construc…
By newseditor
Posted 28 Jan
The role of platelets in im…
By newseditor
Posted 28 Jan
Invariant inhibition to cal…
By newseditor
Posted 27 Jan
Birdsong neuroscience and t…
By newseditor
Posted 27 Jan
Touch neurons underlying do…
By newseditor
Posted 25 Jan
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 10 Mar
ASCO-2020-GYNECOLOGIC CANCER
By newseditor
Posted 10 Mar